Posting of Annual Report and Notice of AGM

LONDON and PHILADELPHIA - May 29, 2026 - Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION^®, a tumor-activated oncology delivery platform, today announces that its Annual Report and Accounts for the year ended December 31, 2025 and the Notice of Annual General Meeting (AGM) are available on the Company's website.

Copies of the Annual Report and Accounts and the Notice of AGM will be posted today to registered shareholders who have elected to receive them in paper form.

The AGM will be held on Monday, June 22, 2026 at 9:00 BST. The meeting will be held at Glaziers Hall, 9 Montague Close, London Bridge, SE1 9DD (the "Venue").

Registered shareholders have a right to attend the AGM.  In addition, the current expectation is that the chair of the AGM will, at their discretion, permit beneficial shareholders to attend in person. Shareholders (registered or beneficial) who propose to attend the AGM in person are requested to pre-register their interest and, to assist the Company in its preparation for the AGM, prove their shareholding by emailing their letter of representation to [email protected] 8.00 p.m. on 20 June 2026. Any failure to pre-register will not, of itself, preclude a registered shareholder from attending the AGM in person (or by proxy).

Only registered shareholders who attend in person or by proxy will be able to vote on the day. Details of how to submit a proxy vote are contained in the Notice of the AGM.

The Company will provide a business update following the AGM, which will be recorded and uploaded on the Company's website for shareholders who are not able to attend in person.  All presentation materials will be made available on the website at the end of the day and no new material information will be provided.

-Ends-

For further information from Avacta, please contact:

About Avacta - https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies through its proprietary pre|CISION® platform. pre|CISION® is a payload delivery system based on a tumor-specific protease (Fibroblast Activation Protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Avacta's innovative pre|CISION® peptide drug conjugates (PDC) are a novel entry to the XDC drug class, leveraging the success of antibody drug conjugates with alternative methods of delivery beyond antibodies. 

Our pre|CISION® PDCs leverage this tumor-specific release mechanism to provide unique benefits over traditional antibody drug conjugates, releasing active payload in the tumor and reducing systemic exposure and toxicity which enables dosing to be optimized to deliver the best outcomes for patients. The lead clinical program is faridoxorubicin (AVA6000), a Gen One FAP-enabled pre|CISION® version of doxorubicin that delivers the payload directly in the tumor with limited peripheral blood exposure and has demonstrated preliminary activity in tumor types sensitive to doxorubicin including salivary gland cancer and soft tissue sarcoma.